363 related articles for article (PubMed ID: 36906823)
1. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
Dexter D; McGann PT
Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
[TBL] [Abstract][Full Text] [Related]
2. Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa.
Ally M; Balandya E
Semin Hematol; 2023 Sep; 60(4):192-199. PubMed ID: 37730472
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
Aneni EC; Hamer DH; Gill CJ
Trop Med Int Health; 2013 Mar; 18(3):313-27. PubMed ID: 23320577
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis.
Kuznik A; Habib AG; Munube D; Lamorde M
BMC Health Serv Res; 2016 Jul; 16():304. PubMed ID: 27461265
[TBL] [Abstract][Full Text] [Related]
6. Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Power-Hays A; Ware RE
Curr Opin Hematol; 2020 May; 27(3):172-180. PubMed ID: 32205588
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa.
Bello-Manga H; DeBaun MR; Kassim AA
Expert Rev Hematol; 2016 Nov; 9(11):1031-1042. PubMed ID: 27677923
[TBL] [Abstract][Full Text] [Related]
8. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
Mvalo T; Topazian HM; Kamthunzi P; Chen JS; Kambalame I; Mafunga P; Mumba N; Chiume M; Paseli K; Tegha G; Kumwenda W; Heimlich JB; Ellis G; Key N; Gopal S; Hoffman I; Ataga KI; Westmoreland KD
Pediatr Blood Cancer; 2019 Nov; 66(11):e27954. PubMed ID: 31397075
[TBL] [Abstract][Full Text] [Related]
10. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
12. Sickle cell disease in children: an update of the evidence in low- and middle-income settings.
Odame I
Arch Dis Child; 2023 Feb; 108(2):108-114. PubMed ID: 35705370
[TBL] [Abstract][Full Text] [Related]
13. Caring for Africa's sickle cell children: will we rise to the challenge?
Oron AP; Chao DL; Ezeanolue EE; Ezenwa LN; Piel FB; Ojogun OT; Uyoga S; Williams TN; Nnodu OE
BMC Med; 2020 Apr; 18(1):92. PubMed ID: 32340612
[TBL] [Abstract][Full Text] [Related]
14. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
[TBL] [Abstract][Full Text] [Related]
17. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
18. [Is therapeutic progress in the management of sickle cell disease applicable in sub-Saharan Africa?].
De Montalembert M; Tshilolo L
Med Trop (Mars); 2007 Dec; 67(6):612-6. PubMed ID: 18300525
[TBL] [Abstract][Full Text] [Related]
19. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.
Green NS; Zapfel A; Nnodu OE; Franklin P; Tubman VN; Chirande L; Kiyaga C; Chunda-Liyoka C; Awuonda B; Ohene-Frempong K; Inusa BPD; Ware RE; Odame I; Ambrose EE; Dogara LG; Oron AP; Willett C; Thompson AA; Berliner N; Coetzer TL; Novelli EM
Blood Adv; 2022 Dec; 6(24):6187-6197. PubMed ID: 36264096
[TBL] [Abstract][Full Text] [Related]
20. Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease.
Dexter D; McGann PT
Br J Haematol; 2022 Jan; 196(1):63-69. PubMed ID: 34340260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
